H F S Negaard

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Angiogenesis and hemostasis in hematological neoplasias
    H Negaard
    Department of Hematology, Ullevaal University Hospital, Kirkeveien 166, 0407 Oslo, Norway
    Curr Drug Targets 6:683-99. 2005
  2. ncbi Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
    Helene F S Negaard
    Department of Haematology, Ulleval University Hospital Trust, Oslo, Norway
    Thromb Haemost 99:1040-8. 2008
  3. ncbi Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
    H F S Negaard
    Department of Haematology, Ulleval University Hospital Trust, Oslo, Norway
    Leukemia 23:162-9. 2009
  4. ncbi Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
    Helene F S Negaard
    Department of Haematology, Oslo University Hospital Ulleval, Oslo, Norway
    Leuk Lymphoma 50:998-1004. 2009
  5. ncbi Increased acquired activated protein C resistance in unselected patients with hematological malignancies
    H F S Negaard
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    J Thromb Haemost 6:1482-7. 2008
  6. ncbi Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
    Helene F S Negaard
    J Clin Oncol 24:2683-4; author reply 2684. 2006

Detail Information

Publications6

  1. ncbi Angiogenesis and hemostasis in hematological neoplasias
    H Negaard
    Department of Hematology, Ullevaal University Hospital, Kirkeveien 166, 0407 Oslo, Norway
    Curr Drug Targets 6:683-99. 2005
    ..A better understanding of this shared biology may reveal new targets, and will probably increase the safety of targeting the blood supply...
  2. ncbi Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
    Helene F S Negaard
    Department of Haematology, Ulleval University Hospital Trust, Oslo, Norway
    Thromb Haemost 99:1040-8. 2008
    ..In conclusion we found a hypercoagulable state in patients with haematological malignancy that did not seem to be initiated by TF...
  3. ncbi Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
    H F S Negaard
    Department of Haematology, Ulleval University Hospital Trust, Oslo, Norway
    Leukemia 23:162-9. 2009
    ..VEGF, IL-6 and IL-8 seem to contribute to the malignant phenotype...
  4. ncbi Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
    Helene F S Negaard
    Department of Haematology, Oslo University Hospital Ulleval, Oslo, Norway
    Leuk Lymphoma 50:998-1004. 2009
    ..After therapy, serum MMP-2 increased while MMP-9 decreased (P < 0.05), the others being unchanged. Several compounds affecting ECM may be involved in angiogenic activity in NHL...
  5. ncbi Increased acquired activated protein C resistance in unselected patients with hematological malignancies
    H F S Negaard
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    J Thromb Haemost 6:1482-7. 2008
    ..Acquired activated protein C (APC) resistance may be another mechanism responsible for such hypercoagulation, and has been demonstrated in patients with solid tumors, but not in patients with hematological malignancy...
  6. ncbi Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
    Helene F S Negaard
    J Clin Oncol 24:2683-4; author reply 2684. 2006